



CIN: L01400TG1986PLC062463

# ARUNJYOTI BIO VENTURES LTD.

To,

Date: 29.05.2023

BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai-400 001

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 29.05.2023**

**Ref: Company's letter dated 08.05.2023**

**Unit: Arunjyoti Bio Ventures Limited (Scrip Code: 530881)**

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Arunjyoti Bio Ventures Limited held on Monday, 29.05.2023 at 4:00 PM at the registered office of the Company at Door No.1-98/1/JSIC/6F/604-B6th Floor, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet Telangana 500081, the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2023. **(Enclosed)**
2. Auditor's Report along with Declaration as per Regulation 33 of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31.03.2023. **(Enclosed)**
3. Non-applicability of submission of Annual Secretarial Compliance Report pursuant to SEBI Circular dated 08.02.2019 and BSE circular dated 09.05.2019 and 14.05.2019. **(Enclosed)**

The meeting concluded at 9.15p.m.

This is for the information and records of the Exchange.

Thanking you.

Yours sincerely,

For Arunjyoti Bio Ventures Limited

P.B.N. Murthy  
Whole-Time Director  
DIN: 01445523

**Arunjyoti Bio Ventures Limited**  
**CIN NO: L01400TG1986PLC062463**  
**Plot No. 45, P & T Colony, Karkhana Secunderabad Hyderabad TG 500009 IN**  
**Financial Position as at March 31, 2023**

Particulars		Note No.	As at Mar 31, 2023	As at Mar 31, 2022
I	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Property, plant and equipment	3	-	-
	(b) Right to use assets		-	-
	(c) Capital work in progress		19,20,06,088	-
	(d) Investment properties		-	-
	(e) Good will		-	-
	(f) Other intangible Assets		-	-
	(g) Intangible Assets under Development		-	-
	(h) Biological Assets other than Bearer Plants		-	-
	(d) Financial assets		-	-
	(i) Investments	4	-	-
	(ii) Trade receivables	5	-	-
	(iii) Loans	6	1,04,627	1,04,627
	(e) Deferred Tax Asset (Net)	7	-	-
	(f) Other non-current asset	8	11,17,72,454	99,05,079
	<b>Total non-current assets (A)</b>		<b>30,38,83,168</b>	<b>1,00,09,705</b>
2	<b>Current assets</b>			
	(a) Inventories	9	88,48,423	-
	(a) Financial assets			
	(i) Investments	4	-	-
	(ii) Trade receivables	5	78,27,895	53,91,456
	(iii) Cash and cash equivalents	10	2,52,169	73,613
	(iv) Bank Balances other than (iii) above		-	-
	(b) Current Tax Asset (Net)	7	-	-
	(c) Other current assets	11	3,84,08,660	54,75,539
	<b>Total current assets (B)</b>		<b>5,53,37,147</b>	<b>1,09,40,608</b>
	Non Current Assets Classified as Held for Sale (C)	11.1	-	-
	<b>Total assets (A+B+C)</b>		<b>35,92,20,315</b>	<b>2,09,50,314</b>
II	<b>EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>			
	(a) Equity share capital	12	2,07,09,000	2,07,09,000
	(b) Other equity	12.1	4,45,857	(6,95,910)
	<b>Total equity (A)</b>		<b>2,11,54,857</b>	<b>2,00,13,090</b>
2	<b>Liabilities</b>			
(i)	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings	13	32,27,17,790	-
	(ii) Trade Payables	14	-	-
	(iii) Other Financial Liabilities	15	-	-
	(b) Long term provisions	16	-	-
	(c) Deferred tax Liabilities(Net)	7	-	-
	(d) Other non Current Liabilities		-	-
	<b>Total non-current liabilities (B)</b>		<b>32,27,17,790</b>	<b>-</b>
(ii)	<b>Current liabilities</b>			
	(a) Financial liabilities			
	(i) Borrowings	13	-	-
	(ii) Trade payables	14	-	1,67,925
	(iii) Other financial liabilities	15	1,28,00,384	-
	(b) Short term provisions	16	-	2,39,838
	(c) Other current liabilities	17	24,13,272	5,29,461
	(d) Current Tax Liabilities (net)	7	-	-
	<b>Total current liabilities (C)</b>		<b>1,52,13,656</b>	<b>9,37,224</b>
	<b>Total liabilities (D=B+C)</b>		<b>33,79,31,446</b>	<b>9,37,224</b>
	<b>Total equity and liabilities (A+D)</b>		<b>35,90,86,303</b>	<b>2,09,50,314</b>

The notes are an integral part of the financial statements

As per our Report of even date

**For V Ravi & Co.,**  
Chartered Accountants  
Firm Reg No:006492S

**Ramesh Kumar D**  
Partner  
Membership No: 217139  
**UDIN: 22217139AJWDHY8894**

Place: Hyderabad  
Date : 29-05-2023

**For and on behalf of the Board of Directors**  
**Arunjyoti Bio Ventures Limited**

**Pabbathi Badari Narayana Murthy**  
Wholtime Director  
DIN:01445523

**Vishal Nadimpally**  
Wholtime Director Cum CFO  
DIN:02745303

<b>PART II - AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2023</b>						
Name of the Company - <b>Arunjyoti Bio Ventures Limited</b>						
Profit and Loss Statement for the Quarter and Year ended <b>31ST MARCH, 2023</b>						
<b>Amounts in Lakhs</b>						
		<b>Quarter Ended</b>			<b>Year Ended</b>	
		<b>3 Months Ended 31/03/2023</b>	<b>Preceeding 3 Months Ended 31/12/2022</b>	<b>Corsp. 3 months ended 31/03/2022</b>	<b>31-03-2023</b>	<b>31-03-2022</b>
		<b>Audited</b>	<b>Unaudited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>
I	Revenue from Operations	125.81	47.72		173.53	297.08
II	Other Income	-	-	27.99	9.50	27.99
<b>III</b>	<b>Total Revenue (I+II)</b>	<b>125.81</b>	<b>47.72</b>	<b>27.99</b>	<b>183.03</b>	<b>325.07</b>
<b>IV</b>	<b>Expenses</b>					
	Cost of Material Consumed	-	-	-	-	-
	Purchase of Stock-in-trade	141.24	96.78	2.59	238.06	287.46
	Changes in inventories of finished goods, Work in progress and Stock in trade	(31.96)	(54.52)	(1.40)	(88.48)	-
	Employee benefits expense	(0.84)	-	2.92	-	6.36
	Finance Costs	(0.50)	-	0.03	-	0.09
	Direct Expenses	-	-	-	-	0.67
	Depreciation and Amortisation expense	-	0.42	-	-	-
	Other Expense	1.03	1.29	0.60	6.82	22.88
	<b>Total Expenses</b>	<b>108.97</b>	<b>43.97</b>	<b>4.74</b>	<b>156.40</b>	<b>317.46</b>
<b>V</b>	<b>Profit/(Loss) from before Prior Period Expenses and tax (I-IV)</b>	<b>16.84</b>	<b>3.75</b>	<b>23.25</b>	<b>26.63</b>	<b>7.61</b>
VI	Prior Period Expenses	-	-	-	-	-
<b>VII</b>	<b>Profit/(Loss) before tax (V-VI)</b>	<b>16.84</b>	<b>3.75</b>	<b>23.25</b>	<b>26.63</b>	<b>7.61</b>
<b>VIII</b>	<b>Tax Expense:</b>					
	Current Tax	-	-	-	4.45	1.98
	Deferred Tax	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	16.84	3.75	23.25	22.17	5.63
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	16.84	3.75	23.25	22.17	5.63
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	16.84	3.75	23.25	22.17	5.63

XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	0.81	0.02	1.12	1.07	0.27
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-	-
XVII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic 2) Diluted	0.81	0.02	1.12	1.07	0.27
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	207.09	207.09	207.09	207.09	207.09
XX	Reservers & Surplus (Excluding Revaluation Reserve)					

**Notes:**

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on 29th May, 2022.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
4. The figures of the current quarter ended 31st March, 2023 and the quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
5. The results are also available on the webiste of the Company [www.orbisagri.com](http://www.orbisagri.com)
6. The Company is engaged in " Tradingof Hardware and Agriculture Inputs" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

For ARUNJYOTI BIO VENTURES LIMITED

Place : Hyderabad  
Date : 29-05-2023

PABBATHI BADARI NARAYAA MURTHY  
Wholetime Director  
(DIN:01445523)

<b>Arunjyoti Bio Ventures Limited</b> <b>CIN NO: L01400TG1986PLC062463</b> <b>Plot No. 45, P &amp; T Colony, Karkhana Secunderabad Hyderabad TG 500009 IN</b> <b>CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2023</b>		
	As at Mar 31, 2023	As at Mar 31, 2022
A	<b>CASH FROM OPERATING ACTIVITIES</b>	
	15,78,828	7,60,222
	(Loss)/Profit before tax and extraordinary items	
	<b>Adjustment for:</b>	
	-	-
	Income tax expense recognised in profit or loss	
	-	-
	Finance costs recognised in profit or loss	
	-	-
	Investment income recognised in profit or loss	
	-	-
	Gain on disposal of property, plant and equipment	
	-	-
	Gain on disposal of a subsidiary	
	-	-
	Gain on disposal of interest in former associate	
	-	-
	Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	
	-	-
	Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	
	-	-
	Net loss/(gain) arising held for trading financial liabilities	
	-	-
	Hedge ineffectiveness on cash flow hedges	
	-	-
	Net (gain)/loss on disposal of available-for-sale financial assets	
	-	-
	Impairment loss recognised on trade receivables	
	-	-
	Reversal of impairment loss on trade receivables	
	-	-
	Depreciation and amortisation of non-current assets	
	-	-
	Transfers from Profit & Loss	
	-	-
	Net foreign exchange (gain)/loss	
	-	-
	Expense recognised in respect of equity-settled share-based payments	
	-	-
	Expense recognised in respect of shares issued in exchange for goods/services	
	-	-
	Amortisation of financial guarantee contracts	
	-	-
	<b>15,78,828</b>	<b>7,60,222</b>
	<b>Operating Profit before Working Capital Changes</b>	
	<b>Movement for Working Capital:</b>	
	(24,36,439)	1,29,89,913
	Increase in trade and other receivables	
	-	-
	(Increase)/decrease in amounts due from customers under construction contracts	
	(88,48,423)	2,59,478
	(Increase)/decrease in inventories	
	(2,01,32,737)	(1,41,558)
	(Increase)/decrease in other assets	
	(1,67,925)	(1,29,35,286)
	Decrease in trade and other payables	
	-	-
	Increase/(decrease) in amounts due to customers under construction contracts	
	(2,39,838)	-
	Increase/(decrease) in provisions	
	-	-
	(Decrease)/increase in deferred revenue	
	18,83,063	(1,37,10,030)
	(Decrease)/increase in other liabilities	
	<b>Changes in non current assets and liabilities</b>	
	-	1,48,66,565
	Decrease/(Increase) in loans & advances	
	-	-
	Decrease/(Increase) in Long Term Provisions	
	(10,18,67,375)	(99,05,079)
	Decrease/(Increase) in Other non Current Assets	
	<b>(13,02,30,845)</b>	<b>(78,15,775)</b>
	<b>Cash generated from operations</b>	
	-	-
	- Income taxes paid	
	<b>(13,02,30,845)</b>	<b>(78,15,775)</b>
	<b>Net Cash flow before extraordinary items</b>	
	-	-
	- Extraordinary & Prior period items	
	<b>(13,02,30,845)</b>	<b>(78,15,775)</b>
	<b>NET CASH FROM OPERATING ACTIVITIES</b>	
	<b>(13,02,30,845)</b>	<b>(78,15,775)</b>
B	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>	
	-	-
	Payments to acquire financial assets	
	-	-
	Proceeds on sale of financial assets	
	-	-
	Interest received	
	-	-
	Royalties and other investment income received	
	-	-
	Dividends received from associates	
	-	-
	Other dividends received	
	-	-
	Amounts advanced to related parties	
	-	-
	Repayments by related parties	
	-	-
	Payments for property, plant and equipment	
	(19,20,06,088)	-
	Proceeds from disposal of property, plant and equipment	
	-	-
	Payments for investment property	
	-	-
	Proceeds from disposal of investment property	
	-	-
	Payments for intangible assets	
	-	-
	Net cash outflow on acquisition of subsidiaries	
	-	-
	Net cash inflow on disposal of subsidiary	
	-	-
	Net cash inflow on disposal of associate	
	-	-
	<b>(19,20,06,088)</b>	-
	<b>NET CASH FROM INVESTING ACTIVITIES</b>	

		-	-
C	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from issue of equity instruments of the Company	-	-
	Proceeds from issue of convertible notes	-	-
	Payment for share issue costs	-	-
	Payment for buy-back of shares	-	-
	Payment for share buy-back costs	-	-
	Proceeds from issue of redeemable preference shares	-	-
	Proceeds from issue of perpetual notes	-	-
	Payment for debt issue costs Proceeds from borrowings	-	-
	Proceeds from borrowings	32,27,17,790	-
	Proceeds from government loans	-	-
	Proceeds on disposal of partial interest in a subsidiary that does not involve loss of control	-	-
	Dividends paid on redeemable cumulative preference shares	-	-
	Dividends paid to owners of the Company	-	-
	Interest paid	-	-
	Long Term Provisions	-	-
	<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>32,27,17,790</b>	-
	<b>NET INCREASE IN CASH &amp; CASH EQUIVALENTS</b>	<b>4,80,857</b>	<b>(78,15,775)</b>
	<b>Cash and cash equivalents at the beginning of the year 1.04.2022</b>	73,613	80,87,045
	Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-
	<b>Cash and cash equivalents at the end of the year as on 31.03.2023</b>	<b>5,54,470</b>	<b>2,71,270</b>
<b>Reconciliation of cash and cash equivalents as per the cash flow Statement</b>			
	Cash and cash equivalents (Note-10.1)	2,52,169	73,613
	Bank overdraft		
	<b>Balance as per statement of cash flows</b>	<b>2,52,169</b>	<b>73,613</b>
The notes are an integral part of the financial statements			
As per our Report of even date			
<b>For V Ravi &amp; Co.,</b>		<b>For and on behalf of the Board of Directors</b>	
Chartered Accountants		Arunjyoti Bio Ventures Limited	
Firm Reg No:006492S			
<b>Ramesh Kumar D</b>		<b>Pabbathi Badari Narayana Murthy</b>	
Partner		Wholtime Director	
Membership No: 217139		DIN:01445523	
<b>UDIN: 22217 139AJWDHY8894</b>		<b>Vishal Nadimpally</b>	
Place: Hyderabad		Wholtime Director Cum CFO	
Date : 29-05-2023		DIN:02745303	



**Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

**To the Board of Directors of ARUNJYOTI BIO VENTURES LIMITED**

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone annual financial results of **ARUNJYOTI BIO VENTURES LIMITED** hereinafter referred to as 'the Company' for the quarter and year ended March 31, 2023 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the company for the year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Standalone Financial Results**

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and

**Branches :**


**Head Office :**

Gr Floor, 2-6-1071,  
Road No.2, KLN Reddy Colony  
Hanamkonda, Warangal Urban Dist  
Telangana - 506 001  
Mobile : 96521 08456  
vraviandco.ca@gmail.com

**Hyderabad :**  
H.No. 1-74/DH/301,  
Diamond Hills, Gachibowli  
Hyderabad.  
Telangana - 500 032  
Mobile : 90321 22231  
rajenderrao@gmail.com

**Karimnagar :**  
10-3-239,  
Vidyanagar  
Karimnagar  
Telangana - 505 001  
Mobile : 99893 13399  
rkdannapuneni@gmail.com

**Hanamkonda :**  
1-7-900/A/61,  
Nandi Hills, Hunter Road  
Hanamkonda, Warangal Urban Dist.  
Telangana - 506 001  
Mobile : 99894 15638  
wglauditors@gmail.com



other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness





of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matters:**

The statement includes the results for the quarter ended March 31, 2023 being the balance figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

**For V RAVI & CO.,**  
Chartered Accountants  
Firm Registration No.006492S



**D. RAMESH KUMAR**  
Partner  
Membership No.217139  
UDIN: 23217139BGUDGY1923

Date: 29.05.2023  
Place: Hyderabad



# ARUNJYOTI BIO VENTURES LTD.

To,

Date: 29.05.2023

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai – 400001

Dear Sir,

**Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.**

**Ref: Arunjyoti Bio Ventures Limited (BSE Scrip Code –530881)**

I, PBN Murthy, Whole-Time Director of M/s. Arunjyoti Bio Ventures Limited hereby declare that, the Statutory Auditors of the company, M/s. V. Ravi & Co, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results (Standalone) of the company for the quarter and year ended 31st March, 2023.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide. Circular No.CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,  
For Arunjyoti Bio Ventures Limited

P.B.N. Murthy  
Whole-Time Director  
DIN: 01445523



# ARUNJYOTI Bio VENTURES Ltd.

To,

Date: 29.05.2023

BSE Limited  
P J Towers, Dalal Street,  
Mumbai-400001

Dear Sir/ Madam,

**Sub: Non-applicability of Annual Secretarial Compliance Report for the year ended 31.03.2023**

**Ref: Scrip Code: 530881**

With reference to the subject cited, we submit to the Exchange that Annual Secretarial Compliance Report pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirement) (Amendment) Regulations, 2018 read with SEBI Circular dated 08.02.2019 and BSE circular dated 08.02.2019, 09.05.2019, 14.05.2019 and 31.03.2021 is not applicable to the Company as it does not attract provisions of Reg 15(2) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 on Corporate Governance since paid up equity share capital is Rs. 2,07,09,000 as on 31.03.2023 which is not exceeding Rs. 10 Crores and the net worth of the Company has not exceeded Rs. 25 Crores as on the last day of previous financial year (i.e., 31.03.2023).

In view of the above, we would like to submit that Arunjyoti Bio Ventures Limited is not required to submit Annual Secretarial Compliance Report for the year ended 31.03.2023 to the Stock Exchange pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirement) (Amendment) Regulations, 2018.

This is for the kind information and records of the Exchange, please.

Thanking you.

Yours sincerely,  
For Arunjyoti Bio Ventures Limited

P.B.N. Murthy  
Whole-Time Director  
DIN: 01445523